Икземпра – новые возможности цитостатической терапии рака молочной железы


Е.В. Лубенникова, Л.Г. Жукова, Э.А. Арутюнян

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России, Москва
Современная фармакотерапия рака молочной железы развивается по пути таргетной и иммунотерапии. Появление нового цитостатического препарата – редкое событие в наши дни. Однако в реальной клинической практике такие препараты остаются востребованными, особенно остро – для больных, не имеющих мишеней для специального лечения. Иксабепилон – представитель нового класса цитостатиков с уникальным антимитотическим действием, доказавший свою эффективность при резистентных формах рака молочной железы.

Литература


1. DeSantis C., Siegel R., Bandi P., Jemal A. Breast cancer statistics, 2011.CA Cancer J. Clin. 2011;61(6):408–18.

2. Larkin J.M.G., Kaye S.B. Epothilones in the treatment of cancer. Expert Opin Investigational Drugs. 2006;15(6):691–702.

3. Lee F.Y.F., Borzilleri R., Fairchild C.R., Kim S.H., Long B.H., Reventos-Suarez C., Vite G.D., Rose W.C., Kramer R.A. Experimental Therapeutics, Preclinical Pharmacology-BMS-247550: A Novel Epothilone Analog with a Mode of Action Similar to Paclitaxel but Possessing Superior Antitumor Efficacy. Clin. Cancer Res. 2001;7(5):1429–37.

4. Dumontet C., Jordan M.A., Lee F.F.Y. Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies. Mol. Cancer tHer. 2009;8(1):17–25.

5. Lee F.Y.F., Covello K.L., Castaneda S., Hawken D.R., Kan D., Lewin A., Wen M.L., Ryseck R.P., Fairchild C.R., Fargnoli J., Kramer R. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin. Cancer Res. 2008;14(24):8123–31.

6. Low J.A., Wedam S.B., Lee J.J., Berman A.W., Brufsky A., Yang S.X., Poruchynsky M.S., Steinberg S.M., Mannan N., Fojo T., Swain S.M. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J. Clin. Oncol. 2005;23(12):2726–34.

7. Thomas E., Tabernero J., Fornier M., Conté P., Fumoleau P., Lluch A., Vahdat L.T., Bunnell C.A., Burris H.A., Viens P., Baselga J., Rivera E., Guarneri V., Poulart V., Klimovsky J., Lebwohl D., Martin M. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol. 2007;25(23):3399–406.

8. Perez E.A., Lerzo G., Pivot X., Thomas E., Vahdat L., Bosserman L., Viens P., Cai C., Mullaney B., Peck R., Hortobagyi G.N. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 2007;25(23):3407–14.

9. Roché H., Yelle L., Cognetti F., Mauriac L., Bunnell C., Sparano J., Kerbrat P., Delord J.P., Vahdat L., Peck R., Lebwohl D., Ezzeddine R., Curé H. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol. 2007;25(23):3415–20.

10. Denduluri N., Low J.A., Lee J.J., Berman A.W., Walshe J.M., Vatas U., Chow C.K., Steinberg S.M., Yang S.X., Swain S.M. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J. Clin. Oncol. 2007;25(23):3421–27.

11. Thomas E.S., Gomez H.L., Li R.K., Chung H.C., Fein L.E., Chan V.F., Jassem J., Pivot X.B., Klimovsky J.V., de Mendoza F.H., Xu B., Campone M., Lerzo G.L., Peck R.A., Mukhopadhyay P., Vahdat L.T., Roché H.H. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 2007;25(33):5210–17.

12. Sparano J.A., Vrdoljak E., Rixe O., Xu B., Manikhas A., Medina C., Da Costa S.C., Ro J., Rubio G., Rondinon M., Perez Manga G., Peck R., Poulart V., Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2010;28(20):3256–63.

13. Hortobagyi G.N., Gomez H.L., Li R.K., Chung H.C., Fein L.E., Chan V.F., Jassem J., Lerzo G.L., Pivot X.B., Hurtado de Mendoza F., Xu B., Vahdat L.T., Peck R.A., Mukhopadhyay P., Roché H.H. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res. Treat. 2010;122(2):409–18.

14. Fornier M. Ixabepilon plus capecitabin for breast cancer patients with an Early metastatic relapse after adjuvant chemotherapy: two clinical trials. Clin. Breast Cancer. 2010;10(5):352–58.

15. Rugo H.S., Campone M., Amadori D., Aldrighetti D., Conte P., Wardley A., Villanueva C., Melisko M., McHenry M.B., Liu D., Lee F., Pivot X. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res. Treat. 2013;139(2):411–19.

16. Rugo H.S., Barry W.T., Moreno-Aspitia A., Lyss A.P., Cirrincione C., Leung E., Mayer E.L., Naughton M., Toppmeyer D., Carey L.A., Perez E.A., Hudis C., Winer E.P. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J. Clin. Oncol. 2015;33(21):2361–69.

17. Towle M.J., Salvato K.A., Budrow J., Wels B.F., Kuznetsov G., Aalfs K.K., Welsh S., Zheng W., Seletsky B.M., Palme M.H., Habgood G.J., Singer L.A., Dipietro L.V., Wang Y., Chen J.J., Quincy D.A., Davis A., Yoshimatsu K., Kishi Y., Yu M.J., Littlefield B.A. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61(3):1013–21.

18. Vahdat L.T., Garcia A.A., Vogel C., Pellegrino C., Lindquist D.L., Iannotti N., Gopalakrishna P., Sparano J.A. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res. Treat. 2013;140(2):341–51.

19. Moulder S., Li H., Wang M., Gradishar W.J., Perez E.A., Sparano J.A., Pins M., Yang X., Sledge G.W. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res. Treat. 2010;119(3):663–71.

20. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001;344(11):783–92.

21. Robert N., Leyland-Jones B., Asmar L., Belt R., Ilegbodu D., Loesch D., Raju R., Valentine E., Sayre R., Cobleigh M., Albain K., McCullough C., Fuchs L., Slamon D. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2–overexpressing metastatic breast cancer. J. Clin. Oncol. 2006;24(18):2786–92.

22. Awada A., Piccart M.J., Jones S.F., Peck R.A., Gil T., Lebwohl D., Wu C.Y., Burris H.A. 3rd. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemother. Pharmacol. 2009;63(3):417–25.

23. Tolaney S.M., Najita J., Chen W., et al. A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer. Cancer Res. 2009;69(abstr. 3137).

24. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., Wickerham D.L., Begovic M., DeCillis A., Robidoux A., Margolese R.G., Cruz A.B. Jr, Hoehn J.L., Lees A.W., Dimitrov N.V., Bear H.D. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 1998;16(8):2672–85.

25. Bear H.D., Anderson S., Smith R.E., Geyer C.E. Jr, Mamounas E.P., Fisher B., Brown A.M., Robidoux A., Margolese R., Kahlenberg M.S., Paik S., Soran A., Wickerham D.L., Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 2006;24(13):2019–27.

26. Baselga J., Zambetti M., Llombart-Cussac A., Manikhas G., Kubista E., Steger G.G., Makhson A., Tjulandin S., Ludwig H., Verrill M., Ciruelos E., Egyhazi S., Xu L.A., Zerba K.E., Lee H., Clark E., Galbraith S. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J. Clin. Oncol. 2008;27(4):526–34.

27. Horak C.E., Pusztai L., Xing G., Trifan O.C., Saura C., Tseng L.M., Chan S., Welcher R., Liu D. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. Clin. Cancer Res. 2013;19(6):1587–95.

28. Campone M., et al. UCBG intergroup: 3-years efficacy result of the Unicancer-PACS08 trial including poor prognosis patients treated with docetaxel or ixabepilone in adjuvant setting. Cancer Res. 2016;abstract P1-12-06.

29. Clinical Trials Databse: NCT00630032. www.clinicaltrials.gov/show/NCT00630032.

30. Denise A., et al. TITAN: Phase III study of doxorubicin/cyclophosphamide (AC) followed by ixabepilona (Ixa) or paclitaxel (Pac) in early-stage, triple-ngative breast cancer (TNBC). J. Clin. Oncol. 2015; abstract 1000.

31. Kassam F., Enright K., Dent R., Dranitsaris G., Myers J., Flynn C., Fralick M., Kumar R., Clemons M. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin. breast cancer. 2009;9(1):29–33.

32. Perez E.A., Patel T., Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res. Treat. 2010;121(2):261–71.


Об авторах / Для корреспонденции


Автор для связи: Е.В. Лубенникова – врач-онколог отделения химиотерапии и комбинированного лечения злокачественных опухолей ФГБУ РОНЦ им. Н.Н. Блохина МЗ РФ, Москва; тел. 8 (499) 324-96-80, e-mail: lubennikova@yandex.ru


Похожие статьи


Бионика Медиа